Absence of a Memory Effect for the Insulinotropic Action of Glucagon-like Peptide 1 (GLP-1) in Healthy Volunteers

Hormone and Metabolic Research

Volumn 35, Issue 9, 2003, Pages 551-556

  Meier, S ^a   Hucking K ^a   Ritzel, R ^a   Holst, J J ^b   Schmiegel, W H ^a   Nauck, M A ^a,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

Glucose Competence; Incretin; Memory Effect; Priming Effect; Time Dependent Activation

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; IMMUNOASSAY; INSULIN LIKE ACTIVITY; MALE; NORMAL HUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; C-PEPTIDE; FASTING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; ISLETS OF LANGERHANS; MALE; PEPTIDES; REFERENCE VALUES;

EID: 0141956380     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-42658     Document Type: Article

References (42)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 1987; 2: 1300-1304
2. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at nearphysiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917
3. Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995; 40: 1074-1082
4. Nauck MA. Is glucagon-like peptide 1 and incretin hormone? Diabetologia 1999; 42: 373-379
5. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307
6. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744
7. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673
8. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72
9. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520
10. Fehmann H-C, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinology 1992; 130: 159-166
11. Nauck MA. Glucagonlike peptide 1. Curr Opin Endocrinol Diabetes 1997; 4: 256-261
12. Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes. Exp Clin Endocrinol Diabetes 1997; 105: 187-195
13. 2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131
14. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol (Endocrinol Metab) 1996; 271: E458-E464
15. Ritzel R, Ørskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38: 720-725
16. Nauck MA, Wollschläger D, Werner J, Holst JJ, Ørskov C, Creutzfeld W et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-1553
17. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Åhren B. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 1996; 19: 843-848
18. Grill V. Time and dose-dependencies for priming effect of glucose on insulin secretion. Am J Physiol (Endocrinol Metab) 1981; 240: E24-31
19. Ashby JP, Shirling D. The priming effect of glucose on insulin secretion from isolated islets of Langerhans. Diabetologia 1981; 21: 230-234
20. Zawalich WS, Zawalich KC. Induction of memory in rat pancreatic islets by tolbutamide. Dependence on ambient glucose level, calcium and phosphoinositide hydrolysis. Diabetes 1988; 37: 816-823
21. Zawalich WS. Glyburide priming of beta cells. Possible involvement of phosphoinositide hydrolysis. Biochem Pharmacol 1991; 41: 807-813
22. Fehmann HC, Göke R, Göke B, Bachle R, Wagner B, Arnold R. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas. Biochim Biophys Acta 1991; 1091: 356-363
23. Borg LA, Westberg M, Grill V. The priming effect of glucose on insulin release does not involve redistribution of secretory granules within the pancreatic B-cell. Mol Cell Endocrinol 1988; 56: 219-225
24. 2+-dependent protein kinase in glucose memory in the rat. Acta Endocrinol (Copenh) 1988; 118: 204-208
25. N'Guyen JM, Magnan C, Laury MC, Thibault C, Leveteau J, Gilbert M et al. Involvement of the autonomic nervous system in the in vivo memory to glucose of pancreatic beta cell in rats. J Clin Invest 1994; 94: 1456-1462
26. Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997; 27: 533-536
27. Nauck MA, Meier S, Holst JJ, Hücking K, Ritzel R, Schmiegel W. Lack of 'memory effect' for insulinotropic action of glucagon-like peptide 1 (GLP-1) (abstract). Diabetes 2000; 49: A227
28. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273; E981-E988
29. Nauck MA, Weber I, Bach I, Richter S, Ørskov C, Holst JJ et al. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2-diabetic patients. Diabetic Med 1998; 15: 937-945
30. Holst JJ. Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982; 207:381-388
31. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957
32. Grandt D, Sieburg B, Sievert J, Schimiczek M, Becker U, Holtmann D. Is GLP-1 (9-36)amide an endogenous antagonist at GLP-1 receptors? (abstract). Digestion 1994; 55: 302
33. Larsen J, Damsbo P. GLP-1 must be present continuously in order to obtain a good glycaemic control in NIDDM (abstract). Diabetes 1997; 46: 186A
34. Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA. Overnight GLP-1 normalizes fasting but not daytime plasma glucose values in NIDDM patients. Exptl Clin Edocrinol Diabetes 1998; 106: 103-107
35. Rachman J, Gribble FM, Levy JC, Turner RC. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 1997; 40: 205-211
36. Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361: 362-365
37. Byrne MM, Brandt A, Arnold R, Katschinski M, Göke B. Glucose-insulin secretory dose-response curves during constant GLP-1 infusion and pretreatment with GLP-1 (abstract). Diabetologia 1999; 42: A78
38. D'Alessio D, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 1994; 93: 2263-2266
39. Lugari R, Del'Anna C, Ugolotti D, Dei Cas A, Barilli AL, Zandomeneghi R et al. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human Type 1 and Type 2 diabetes. Horm Metab Res 2000; 32: 424-428
40. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-23
41. Vilsboslashll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-13
42. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246